Showing 1 - 2 results of 2 for search 'Mirelis Acosta-Rivera', query time: 0.02s
Refine Results
-
1
P882: POMALIDOMIDE, DARATUMUMAB, AND DEXAMETHASONE AFTER LENALIDOMIDE TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): FINAL OVERALL SURVIVAL ANALYSIS OF... by Nizar J Bahlis, Christy Samaras, Donna Reece, Michael Sebag, Jeffrey Matous, Jesus Berdeja, Jesse Shustik, Gary Schiller, Siddhartha Ganguly, Kevin Song, Christopher S. Seet, Mirelis Acosta-Rivera, Donald Quick, Bertrand Anz, Gustavo Fonseca, Unicel-Anne Flores, Hongjuan Liu, Christian Gentili, David Siegel
Published 2023-08-01
Article -
2
BMS-986012, an Anti–Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study by Quincy Chu, MD, Natasha B. Leighl, MD, Veerle Surmont, MD, Carla van Herpen, MD, PhD, Anne Sibille, MD, Ben Markman, MD, Stephen Clarke, MD, Rosalyn A. Juergens, MD, PhD, Mirelis Acosta Rivera, MD, Vladimir Andelkovic, MD, Charles M. Rudin, MD, PhD, Stephanie Snow, MD, Dong-Wan Kim, MD, Michael Sanatani, MD, Hongxia Lin, PhD, Kinjal Sanghavi, PhD, Sarah Tannenbaum-Dvir, MD, Paul Basciano, MD, Deanne Lathers, PhD, Katarzyna Urbanska, PhD, Georgia Kollia, PhD, Chunsheng He, PhD, Andrew DiPiero, BS, Yu Liu, MD, PhD, Neal Ready, MD, PhD
Published 2022-11-01
Article